{"id":"W3179641925","doi":"10.1007/s10637-021-01146-x","title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Toxicity; Cancer; Radioimmunotherapy; Antibody-drug conjugate; Phases of clinical research; Gastroenterology; Antibody; Oncology; Pharmacology; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009107349,0.001360681,0.001739563,0.0004602234,0.0005094177,0.0008330787,0.0006262065,0.001475033,0.003477606],"category_scores_gemma":[0.0007187017,0.0005509316,0.001133952,0.0003907976,0.0007569087,0.0006749241,0.0002754062,0.00302049,0.0009280983],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007342537,"about_ca_system_score_gemma":0.001316741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001676653,"about_ca_topic_score_gemma":0.003222812,"domain_scores_codex":[0.9997346,0.0001075974,0.000007853619,0.0000486305,0.00002386014,0.00007747882],"domain_scores_gemma":[0.9995739,0.00009184737,0.00004456344,0.00002882527,0.00002522882,0.0002355653],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.536567,0.1171697,0.007699546,0.001180943,0.00133764,0.0015442,0.001000925,0.01110618,0.1414545,0.001312717,0.01404148,0.1655851],"study_design_scores_gemma":[0.3914531,0.5806677,0.00957686,0.00003172155,0.0003170088,0.0008160294,0.0001142378,0.00276594,0.008350247,0.0003813186,0.005473158,0.00005257644],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9898085,0.001882342,0.001050628,0.0007603261,0.0001834024,0.002129676,0.001224895,0.0001192244,0.002841076],"genre_scores_gemma":[0.9876581,0.001935404,0.001667117,0.0008955016,0.0001210882,0.001689968,0.002209549,0.0000474279,0.003775838],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003477606,"threshold_uncertainty_score":0.01163375,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01728077159289466,"score_gpt":0.3150924209845254,"score_spread":0.2978116493916308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}